It is not credible for institutions to treat company behaviour as external to system performance, particularly in the context of a more assertive US stance on pharmaceutical pricing. Yet what review processes exist are mostly about additional adjustments by stakeholders to the institutional framework. How about changing the framework to recognise realities? …
The importance of humility and understanding the other side of the equation
March 22, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials cite company consultation, system changes, and spending approvals to justify delay
June 4, 2026 - - Latest News -
An exchange that reveals the truth of a review that has now become a lot like 'Weekend at Bernie's'
June 3, 2026 - - Latest News -
Invitation confusion clouds Delphi studies and captures medical device sector
June 3, 2026 - - Latest News -
Patient voices take centre stage at the 2026 Patient's Choice Awards
June 3, 2026 - - Latest News